Cingulate (CINGW) Long-Term Debt Issuances (2021)
Cingulate's (CINGW) quarterly Long-Term Debt Issuances came in at $350335.0 in Q4 2021, up 401.99% quarter-over-quarter from $69789.0 in Q1 2021.
Powered by 
Analysis
Cingulate (CINGW) Long-Term Debt Issuances (2021) Analysis & Trends
Cingulate (CINGW) has reported Long-Term Debt Issuances for 1 consecutive years, with $350335.0 the latest figure, recorded in Q4 2021.
- For the quarter ending Q4 2021, Long-Term Debt Issuances changed N/A year-over-year to $350335.0; the trailing twelve-month figure through Dec 2023 stood at $350335.0 (changed N/A YoY), and the FY2025 full-year result was $6.0 million, up 20.87% from the prior year.
- Long-Term Debt Issuances climbed to $350335.0 in Q4 2021 per CINGW's latest filing, from $69789.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $350335.0 in Q4 2021 and bottomed at $69789.0 in Q1 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.10 Bn | 625.34 Bn | 17.26 Bn | - |
| 2 | AbbVie | 441.68 Bn | 435.11 Bn | 12.70 Bn | - |
| 3 | Merck | 366.62 Bn | 359.48 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 266.55 Bn | 258.86 Bn | 11.24 Bn | 1.98 Bn |
| 5 | Pfizer | 159.14 Bn | 147.45 Bn | 10.94 Bn | - |
| 6 | Sanofi | 52.40 Bn | 45.02 Bn | 10.79 Bn | 4.88 Bn |
| 7 | Revolution Medicines | 44.07 Bn | 44.07 Bn | - | - |
| 8 | Incyte | 25.59 Bn | 21.05 Bn | 1.57 Bn | - |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn | - |
| 10 | Cingulate | 100,214.03 | 100,214.03 | - | - |